Corrigendum to "Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus" [Heliyon 9(4) (April 2023) e15032]
Heliyon. 2023 Jul 6;9(8):e17901.
doi: 10.1016/j.heliyon.2023.e17901.
eCollection 2023 Aug.
1 Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research U.S. FDA, Silver Spring, MD, USA.
2 Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
3 Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA.
4 Dept. of Biochemistry and Molecular Biophysics, University of Pennsylvania, Philadelphia, PA, USA.
5 Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
6 The Institute for Protein Innovation, Boston, MA, USA.
7 Institute for Quantitative Biomedicine, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
8 Program in Molecular Biophysics, Johns Hopkins University, Baltimore, MD, USA.
9 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
10 Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD, USA.